Indacaterol
ARCAPTA
What it isOnce-daily long-acting beta-2 agonist; COPD maintenance.
Why this oneTwenty-four-hour bronchodilation with a rapid onset, unusual for a LABA.
What limits itNever as monotherapy in asthma. Cough immediately after inhalation is characteristic.
FDA-approved for
- COPD (2011)
NO BOXED WARNINGS
Principal riskNever as monotherapy in asthma; post-inhalation cough
Classes and tags
Clinical profile
Mechanism of action: Indacaterol ballicule
